The functional consequences of partial calcineurin inhibition in human peripheral blood mononuclear leucocytes

Transplant Immunology

Volumn 4, Issue 1, 1996, Pages 23-31

  Pazderka, Feldzgeritta ^a   Enns, Janet ^a   Batiuk, Thomas D ^a   Halloran, Philip F ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMYCIN; CALCINEURIN; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 2; MESSENGER RNA; OKT 3;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0030011176     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(96)80029-3     Document Type: Article

References (38)

1. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation. Science 1989; 243: 355-61.
2. Handschumacher RE, Harding MW, Rice J et al. Cyclophilin, a specific cytosolic binding protein for cyclosporine A. Science 1984; 226: 544-47.
3. Harding MW, Galat A, Uehling DE et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341: 758-60.
4. Liu J, Farmer JD Jr, Lane WS et al. Calcineurin is a common target. for cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15.
5. McCaffrey PG, Luo C, Kerppola TK et al. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science 1993; 262: 750-54.
6. p is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993; 365: 352-55.
7. Fruman DA, Klee CB, Bierer BE et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89: 3686-90.
8. Starzl TE, Klintmalm GBG, Weill R III et al. Cyclosporine A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 1981; 153: 486-94.
9. Fathman CG, Myers BD. Cyclosporine therapy for autoimmune disease. N Engl J Med 1992; 326: 1693-95.
10. Noronha IL, Eberlein-Gonska M, Hartley B et al. In situ expression of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 receptors in renal allograft biopsies. Transplantation 1992; 54: 1017-24.
11. von Graffenried B, Harrison WB. Side effects (with emphasis on renal dysfunction) and recommendations for use. In: Schindler R ed. Cyclosporin in autoimmune diseases. Berlin: Springer-Verlag, 1993: 60-73.
12. Palestine AG, Roberge F, Charous BL et al. The effect of cyclosporine on immunization with tetanus and keyhole limpet hemocyanin (KLH) in humans. J. Clin. Immunol 1985; 5: 115-21.
13. Abramowicz D, Schandene L, Goldman M et al. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606-038.
14. Chatenoud L, Ferran C, Reuter A et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-α. N Engl J Med 1989; 320: 1420-21.
15. Batiuk TD, Pazderka F, Halloran PF. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation 1995; 59: 1400-404.
16. Pai SY, Fruman DA, Leong T et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood 1994; 84: 3974-79.
17. Koutouby R, Zucker C, Zucker K et al. Molecular monitoring of the immunosuppressive effects of cyclosporine in renal transplant patients by using a quantitative polymerase chain reaction. Hum Immunol 1993; 36: 227-34.
18. Maniatis T, Fritsch EF, Sambrook J. Molecular clotting: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1982.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem 1987; 162: 156-59.
20. Thomas PS. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA 1980; 77: 5201-205.
21. Woloszczuk W, Troppmair J, Leiter E et al. Relationship of interferon-gamma and neopterin levels during stimulation with alloantigens in vivo and in vitro. Transplantation 1986; 47: 716-19.
22. Batiuk TD, Pazderka F, Enns J et al. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest 1995 96: 1254-60.
23. Bativk TD, Pazderka F, Ems J, De Castro L, Halloran PF. Cyclosporine inhibition of leucocyte calcineurin is much less in whole blood than in culture medium. Transplantation 1996; 61: 158-61.
24. Lensmeyer GL, Wiebe DA, Carlson IH. Distribution of cyclosporin A metabolites among plasma and cells in whole blood: effect of temperature, hematocrit, and metabolite concentration. Clin Chem 1989; 35: 56-63.
25. Hughes TA, Gaber AO, Montgomery CE. Plasma distribution of cyclosporine within lipoprotems and 'in vitro' transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins. Ther Drug Monit 1991; 13: 289-95.
26. Kasiske BL, Awni WM, Heim-Duthoy KL et al. Alterations in cyclosporine pharmacokinetics after renal transplantation are linked to rapid increases in hematocrit, lipoproteins, and serum protein. Transplant Proc 1988; 20: 485-86.
27. 50 for in vivo cyclosporine in mouse. Transplantation 1996 (in press).
28. Madden RL, Schroeder TJ, Alexander TW et al. Single dose OKT3: adverse effects, pharmacokinetics, and anti-OKT3 antibody response. Transplant Sci 1994; 4: 111-14.
29. Goldstein G, Norman DJ, Henell KR et al. Pharmacokinetic study of orthoclone OKT3 serum levels during treatment of acute renal allograft rejection. Transplantation 1988; 46: 587-89.
30. Flanagan WM, Corthesy B, Bram RJ et al. Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A. Nature 1991; 352: 803-807.
31. Nolan GP, Ghosh S, Liou HC et al. DNA binding and IkB inhibition of the cloned p65 subunit of NF-kB, a rel-related polypeptide. Cell 1991; 64: 961-69.
32. Liou H-C, Baltimore D. Regulation of the NF-k/rel transcription factor and IkB inhibitor system. Curr Opin Cell Biol 1993; 5: 477-87.
33. Pimentel-Muinos FX, Mazana J, Fesno M. Biphasic control of nuclear factor kappa B activation by the T cell receptor complex: role of tumor necrosis factor alpha. Eur J Immunol 1995; 25: 179-86.
34. Frantz B, Nordby EC, Bren G et al. Calcineurin acts in synergy with PMA to inactivate IkB/MAD3, an inhibitor of NF-kB. EMBO J 1994; 13: 861-70.
35. Pulverer BJ, Kyriakis JM, Avruch J er al. Phosphorylation of c-jun mediated by MAP kinases. Nature 1991; 353: 670-74.
36. Rineon M, Flavell RA. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J 1994; 13: 4370-81.
37. Su B, Jacinto E, Hibi M et al. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 1994; 77: 727-36.
38. Danilovs JA, Ayoub G, Terasaki PI. B lymphocyte isolation by thrombin-nylon wool. In: Terasaki Pl ed. Histocompatability testing. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1980: 287-88.